Senomyx (SNMX) Misses The Q2 EPS View By 5c
More News related to SNMX
- Beacon Equity Issues Technical Trade Alerts on Market Movers: SSVE, ENZN, SNMX, VECO, STEC, SIMG
- SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
- SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
- SENOMYX RECEIVES GENERALLY RECOGNIZED AS SAFE (GRAS) DETERMINATION FOR S2383 SUCRALOSE ENHANCER
- SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
More News related to Earnings
- Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
- Silicon Motion Technology Corporation Announces Upcoming Schedule of Events With the Financial Community
- First Ever Collector Car Exchange in the United States with China
- Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices
- 2008 Uniform Evaluation: Nine Quebec Candidates Make the National Honour Roll
Senomyx (Nasdaq: SNMX) reports Q2 loss of $0.25, 5 cents lower than the analyst estimate of ($0.20).
Revenues for the quarter were $3.57 million, versus the consensus of $5.44 million.
Senomyx, a biotechnology company, engages in the discovery and development of flavors, flavor enhancers, and taste modulators for the packaged food, beverage, and ingredient industries primarily in the United States.
Related Categories
EarningsStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
